Kate Sears
LightNews LightNews
banner
katesears.bsky.social
Kate Sears
@katesears.bsky.social
1.6K followers 860 following 460 posts
Hi I'm Kate, community lead for Medical.watch. Want practice changing updates in oncology/hematology? Get our weekly newsletter and join 2700+ clinicians.

Subscribe for free: Medical.watch

About us: tinyurl.com/Medicalwatch
Posts Replies Media Videos
katesears.bsky.social
🟡 Single-arm studies with strong biomarker rationale can drive approvals
🟣 Tumor-agnostic evidence, early-line trials & RWE must be included—or we risk undervaluing #PrecisionOncology

#EvidenceBasedMedicine #CancerResearch #ClinicalTrials #PersonalizedMedicine

ascopubs.org/doi/10.1200/...
Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review
ascopubs.org
September 19, 2025 at 5:04 PM
katesears.bsky.social
Can't wait Andrea! 🙂
September 18, 2025 at 10:09 PM
katesears.bsky.social
#Immunotherapy #IOtoxicities
aacrjournals.org/cancerrescom...
Immune activation signatures associated with fatigue in cancer patients undergoing immune checkpoint inhibitor therapy
Abstract. Fatigue is a common and often debilitating adverse event among patients receiving immune checkpoint inhibitor (ICI) therapy, yet its underlying immunologic mechanisms remain poorly defined. ...
aacrjournals.org
September 17, 2025 at 2:38 PM
katesears.bsky.social
✅ GA captured frailty & comorbidities beyond routine clinical eval
⚖️ Supports tailored therapy for older/frail MM pts

#GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #MultipleMyeloma

www.geriatriconcology.net/article/S187...
Prospective comparison between geriatric assessment and clinical evaluation in 200 newly diagnosed older adults with multiple myeloma
Impressive therapeutic progress has been obtained in multiple myeloma (MM) due to the introduction of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and, more recently, T-cell r...
www.geriatriconcology.net
September 16, 2025 at 4:34 PM
katesears.bsky.social
📌 Conclusion:
Neurotoxicity is a major survivorship challenge → need biomarkers, preventive strategies, multidisciplinary management.

#NeuroOncology #Neurotoxicity #CancerSurvivorship #MedEd
September 15, 2025 at 2:36 PM
katesears.bsky.social
💡 Management strategies
🔹CIPN: dose modification, duloxetine, lifestyle interventions
🔹RT: hippocampal-sparing, memantine
🔹IO: steroids, early recognition
September 15, 2025 at 2:36 PM
katesears.bsky.social
🧬 Mechanisms
🔹CIPN: axonal degeneration, ion channel changes, mitochondrial injury
🔹RT: neuroinflammation, vascular damage, neurogenesis impairment
🔹IO: autoimmunity & cytokine-driven CNS effects

🧪 Emerging biomarkers
➡️NfL, GFAP, imaging correlates
September 15, 2025 at 2:36 PM
katesears.bsky.social
🧾 Scope
➡️Peripheral + central neurotoxicity across chemo, RT, IO
➡️Covers CIPN, RT-induced cognitive decline, IO-related neuro events
September 15, 2025 at 2:36 PM
katesears.bsky.social
✅ Surveillance underused despite curative potential
✅ IO-based combos in advanced HCC → OS >2 yrs
➡️ Ongoing need: prevention, early dx, biomarkers & access

#LiverCancer #GIOnc #Immunotherapy
www.jhep-reports.eu/article/S258...
Hepatocellular Carcinoma: Epidemiology, diagnosis and treatment
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide and predominantly affects individuals with cirrhosis. While viral hepatitis has historically been the ma...
www.jhep-reports.eu
September 10, 2025 at 9:39 PM